Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Exelixis Inc. EXEL

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:EXEL)

Fundamentals Snapshot (NDAQ:EXEL)

Current News (NDAQ:EXEL)

Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Business Wire 7 days ago

Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Business Wire July 26, 2022

Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer

Business Wire July 11, 2022

Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

Business Wire July 7, 2022

Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference

Business Wire July 5, 2022

Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer

Business Wire June 21, 2022

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

Business Wire June 16, 2022

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June

Business Wire May 31, 2022

Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022

Business Wire May 26, 2022

Bullboard Posts (NDAQ:EXEL)

FYI (Seeking Alpha) Bret Jensen

I offer up three predictions that are highly probable in my opinion for Gilead in 2017 and its shareholders. 1. The dividend is hiked...
Carlos66 - January 11, 2017

RE:Anyone watching this?

I'm in let see what happen soon?? Mark
mark26 - August 16, 2014

Anyone watching this?

this is going to JUMP! $11 dollar target set by Piper Jaffray... get in this quick!!!
stopstockingme - April 6, 2014

Venture Exchange News EXCELSIOR ENERGY LIMITED ("ELE"...
Oldmannorth - October 9, 2007

RE: Excelsior News - Sept 25

Bye Bye CNQ, hello TSX Venture. New symbol is ELE starts trading Tuesday October 9th.
britexile - October 9, 2007

Just want

to say that the ticker says cc is buying-doesn't mean cc is buying. I sold my stock at another firm and the ticker-say cc, but wasn...
paparico - October 4, 2007